Du är här

2016-02-05

Novavax, Inc.: Novavax Announces Exercise of Over-Allotment Option to Purchase Additional Shares

GAITHERSBURG, Md., Feb. 05, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc.
(Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery,
development and commercialization of recombinant nanoparticle vaccines and
adjuvants, today announced that, in connection with Novavax' previously
announced initial offering of 3.75% Senior Convertible Notes due 2023 (the
"Notes"), the initial purchasers have exercised in part their previously
announced over-allotment option to purchase an additional $25 million
aggregate principal amount of the Notes (the "Additional Notes"). The closing
of the sale of the Additional Notes occurred on February 5, 2016. Following
the closing of the Additional Notes, Novavax has issued a total of $325
million aggregate principal amount of its 3.75% Senior Convertible Notes due
2023. Following today's closing, the initial purchasers retain the option,
expiring February 24, 2016, to purchase up to an additional $5 million
aggregate principal amount of the Notes on the same terms and conditions as
previously disclosed. The Notes were offered and sold only to qualified
institutional buyers pursuant to Rule 144A under the Securities Act of 1933,
as amended.

Citigroup and J.P. Morgan acted as joint book-running managers of the
offering. Piper Jaffray and Guggenheim Securities acted as Co-Lead Managers.

Assuming the initial purchasers do not exercise the remainder of their
over-allotment option, Novavax will have received aggregate net proceeds from
the offering (including the previously-announced net proceeds of
approximately $291 million from the initial closing on January 29, 2016) of
approximately $315 million, after deducting the initial purchasers' discounts
and commissions, but prior to deducting estimated offering expenses. Novavax
used approximately $2.9 million of the net proceeds from the offering of the
Additional Notes to pay the cost of additional capped call transactions
entered into in connection with the partial exercise of the over-allotment
option. The cap price of the capped call transactions will be $9.73 per
share, which represents a premium of approximately 75% based on the last
reported sale price of Novavax' common stock of $5.56 per share on the day of
pricing of the Notes, January 25, 2016, and is subject to certain adjustments
under the terms of the additional capped call transactions.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to
delivering novel products to prevent a broad range of infectious diseases.
Its recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the
foundation for groundbreaking innovation that improves global health through
safe and effective vaccines.

Forward-Looking Statements
This press release contains forward-looking statements. Investors are
cautioned not to place undue reliance on these forward-looking statements,
including, but not limited to, potential exercise by the initial purchasers
of their remaining over-allotment option and the possible effects of the
capped call transactions. Each forward-looking statement is subject to risks
and uncertainties that could cause actual results to differ materially from
those expressed or implied in such statement. Applicable risks and
uncertainties include, but are not limited to, those related to the conduct,
timing and potential results from Novavax' clinical-trials and other
preclinical studies, Novavax' plans for and potential timing of regulatory
filings, the expected timing and content of regulatory actions, Novavax'
plans regarding partnering activities and business development initiatives,
and the timing and success of Novavax' commercialization, if any, of its
product candidates. In addition, Novavax' management retains broad discretion
with respect to the allocation of the net proceeds of this offering.
Applicable risks also include those that are listed under the heading "Risk
Factors" and elsewhere in Novavax' Annual Report on Form 10-K for the fiscal
year ended December 31, 2014, in addition to the risk factors that are
included from time to time in Novavax' subsequent SEC filings. Novavax
undertakes no obligation to update these forward-looking statements to
reflect events or circumstances occurring after this press release. Except as
otherwise noted, these forward-looking statements speak only as of the date
of this press release. All forward-looking statements are qualified in their
entirety by this cautionary statement.

Contact:

Novavax, Inc.

Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations

ir@novavax.com
240-268-2000

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire

HUG#1984212

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.